Why Some Autoimmune Diseases Are Hard to Treat

A review published in The Lancet Rheumatology proposes a broader and more empathetic framework for managing autoimmune diseases that don’t respond to standard treatments. Known as “difficult-to-treat” conditions, these cases include not only biologically refractory disease but also challenges like misdiagnosis, medication side effects, comorbidities, and psychosocial barriers to care.

The article traces how “treat-to-target” strategies have improved outcomes in diseases like rheumatoid arthritis but notes that many patients still struggle despite appropriate therapy. Definitions of difficult-to-treat disease now exist for several autoimmune conditions—including lupus, psoriatic arthritis, and inflammatory bowel disease—with others in development.

By emphasizing shared decision-making, personalized treatment targets, and a multidisciplinary approach, the authors argue for shifting away from a one-size-fits-all mindset. For patients with autoimmune conditions, this could mean more inclusive research designs, expanded treatment pathways, and a clinical model that better reflects the complex nature of their diseases.

Citation

Nagy, G., et al. (2025). The concept of difficult-to-treat disease in rheumatology: where next?. The Lancet. Rheumatology, 7(4), e274–e289. https://doi.org/10.1016/S2665-9913(24)00340-0